PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) EVP Alaleh Nouri sold 30,432 shares of the firm's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $62.97, for a total value of $1,916,303.04. Following the transaction, the executive vice president now directly owns 62,472 shares in the company, valued at $3,933,861.84. The sale was disclosed in a document filed with the SEC, which is available at this link.
Alaleh Nouri also recently made the following trade(s):
- On Monday, March 18th, Alaleh Nouri sold 441 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $48.83, for a total transaction of $21,534.03.
- On Wednesday, March 6th, Alaleh Nouri sold 2,749 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $46.67, for a total transaction of $128,295.83.
- On Friday, February 9th, Alaleh Nouri sold 14,694 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $49.97, for a total transaction of $734,259.18.
- On Wednesday, February 7th, Alaleh Nouri sold 5,306 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $49.95, for a total transaction of $265,034.70.
PROCEPT BioRobotics Price Performance
Shares of PRCT stock opened at $64.31 on Friday. The company has a current ratio of 7.63, a quick ratio of 6.77 and a debt-to-equity ratio of 0.18. The business's 50 day moving average price is $50.25 and its 200-day moving average price is $43.61. PROCEPT BioRobotics Co. has a fifty-two week low of $24.83 and a fifty-two week high of $64.89.
Elon’s New Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.04. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 42.13%. The business had revenue of $44.50 million for the quarter, compared to analysts' expectations of $41.58 million. During the same quarter in the previous year, the business posted ($0.63) earnings per share. The firm's revenue for the quarter was up 82.4% compared to the same quarter last year. On average, sell-side analysts forecast that PROCEPT BioRobotics Co. will post -1.98 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on PRCT shares. Truist Financial boosted their target price on PROCEPT BioRobotics from $63.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday. Wells Fargo & Company boosted their price objective on PROCEPT BioRobotics from $44.00 to $47.00 and gave the company an "overweight" rating in a research report on Tuesday, January 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $49.50.
View Our Latest Analysis on PRCT
Institutional Trading of PROCEPT BioRobotics
Several institutional investors and hedge funds have recently bought and sold shares of PRCT. FMR LLC raised its position in shares of PROCEPT BioRobotics by 13.0% in the 3rd quarter. FMR LLC now owns 7,553,460 shares of the company's stock worth $247,829,000 after acquiring an additional 870,364 shares in the last quarter. Wellington Management Group LLP purchased a new stake in PROCEPT BioRobotics in the third quarter worth $26,404,000. Loomis Sayles & Co. L P raised its holdings in PROCEPT BioRobotics by 89.8% in the third quarter. Loomis Sayles & Co. L P now owns 1,345,454 shares of the company's stock worth $44,144,000 after purchasing an additional 636,750 shares in the last quarter. Vanguard Group Inc. lifted its position in PROCEPT BioRobotics by 10.4% during the third quarter. Vanguard Group Inc. now owns 4,074,891 shares of the company's stock valued at $133,697,000 after buying an additional 385,271 shares during the period. Finally, Artisan Partners Limited Partnership bought a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at $15,533,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.
About PROCEPT BioRobotics
(
Get Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
